Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › inclisiran

inclisiran

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of inclisiran

14 trials tracked of inclisiran: 12 in phase 3 or 4 and 11 with published results. The most-cited published study has 1607 citations.

14Trials tracked
12Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 1 Phase 3 11 Phase 2 2
  1. Phase 3 Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol Completed · 1,607 cited
  2. Phase 3 Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol Completed · 1,593 cited
  3. Phase 3 Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) Completed · 814 cited
  4. Phase 3 Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C Completed · 91 cited
  5. Phase 3 A Randomized Study to Evaluate the Effect of an "Inclisiran First" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE) Completed · 76 cited
  6. Phase 3 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia Completed · 65 cited
Show 8 more trials
  1. Phase 3 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia Completed · 65 cited
  2. Phase 3 Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy. Completed · 19 cited
  3. Phase 3 Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support Completed · 13 cited
  4. Phase 3 Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome Completed · 2 cited
  5. Phase 4 Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia Completed · 1 cited
  6. Phase 3 Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. Completed
  7. Phase 2 Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C Completed
  8. Phase 2 An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
PCSK9 inhibitors significantly reduce LDL-C levels in patients with atherosclerotic cardiovascular disease
Cardiology Meta-analysis
PCSK9 inhibitors significantly reduce LDL-C levels in patients with atherosclerotic cardiovascular disease PCSK9 inhibitors lower LDL but not stroke risk
This meta-analysis of 63,328 patients evaluated the efficacy and cost-effectiveness of alirocumab, evolocumab, and inclisiran compared to st…
A large meta-analysis finds PCSK9 inhibitors cut LDL and heart attacks, but stroke risk was unchanged. Evolocumab may offer the best value.
Frontiers Aug 9, 2026
PCSK9 inhibitors reduce LDL-C by 35.44% in children with heterozygous familial hypercholesterolaemia
Cardiology Sys. Review
PCSK9 inhibitors reduce LDL-C by 35.44% in children with heterozygous familial hypercholesterolaemia PCSK9 inhibitors lower LDL cholesterol in children with high risk
This systematic review and meta-analysis of randomized controlled trials found that PCSK9 inhibitors as add-on therapy significantly reduced…
New data shows PCSK9 inhibitors significantly lower bad cholesterol in children who do not reach health goals on standard medications.
medRxiv Aug 9, 2026
Inclisiran reduces LDL cholesterol by up to 54.7% in patients with atherosclerotic cardiovascular disease
Nephrology RCT
Inclisiran reduces LDL cholesterol by up to 54.7% in patients with atherosclerotic cardiovascular disease Trial shows consistent cholesterol reduction for heart disease patients
This Phase 3 randomized controlled trial evaluated inclisiran in 3,660 patients with heterozygous familial hypercholesterolemia and atherosc…
A large trial shows that a new injection can significantly lower bad cholesterol in people with high risk for heart disease.
Jul 4, 2026
Inclisiran plus usual care improves LDL-C goal attainment after acute coronary syndrome
Genetics & Precision Medicine RCT
Inclisiran plus usual care improves LDL-C goal attainment after acute coronary syndrome Inclisiran helps heart patients hit cholesterol goals fast
This phase 3b open-label RCT in 400 patients discharged after acute coronary syndrome found that adding inclisiran to usual care led to sign…
A new shot helped 3 in 4 recent heart attack patients reach LDL targets within 90 days, far more than usual care alone.
May 20, 2026